{'fraction_non_alphanumeric': 0.02345215759849906, 'fraction_numerical': 0.0009380863039399625, 'mean_word_length': 5.427710843373494, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Laboratory evaluation of inherited thrombotic disorders.

(such as bacille Calmette-Guerin and adenovirus), and novel recombinant DNA constructs may yet lead to promising efficacy results as a basis for large-scale testing. In the meantime, high-risk uninfected cohorts are now being recruited and the infrastructure put in place in the United States and abroad for efficacy tests of one or more of the most promising candidate HIV-1 vaccines that may become available in several years. The first vaccines used may be only partially effective, but their early introduction might still prevent many infections, reduce viral transmission, delay disease, and provide valuable information that could facilitate future vaccine development. Multiple vaccines that are tailor-made for the predominant HIV strain(s) circulating at different global sites may need to be tested simultaneously. A longterm commitment has been made to vaccine development; this must include realistic expectations and both preclinical and clinical trials. MURRAY B. GARDNER, MD Davis, California